Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Phosphorylation of connexin 43 at MAPK, PKC or CK1 sites each distinctly alter the kinetics of epidermal wound repair.

Lastwika KJ, Dunn CA, Solan JL, Lampe PD.

J Cell Sci. 2019 Sep 23;132(18). pii: jcs234633. doi: 10.1242/jcs.234633.

PMID:
31427427
2.

Comparison of prediction models with radiological semantic features and radiomics in lung cancer diagnosis of the pulmonary nodules: a case-control study.

Wu W, Pierce LA, Zhang Y, Pipavath SNJ, Randolph TW, Lastwika KJ, Lampe PD, Houghton AM, Liu H, Xia L, Kinahan PE.

Eur Radiol. 2019 Nov;29(11):6100-6108. doi: 10.1007/s00330-019-06213-9. Epub 2019 May 21.

PMID:
31115618
3.

Tumor-derived Autoantibodies Identify Malignant Pulmonary Nodules.

Lastwika KJ, Kargl J, Zhang Y, Zhu X, Lo E, Shelley D, Ladd JJ, Wu W, Kinahan P, Pipavath SNJ, Randolph TW, Shipley M, Lampe PD, Houghton AM.

Am J Respir Crit Care Med. 2019 May 15;199(10):1257-1266. doi: 10.1164/rccm.201804-0628OC.

PMID:
30422669
4.

Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.

Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW.

Melanoma Res. 2017 Dec;27(6):545-557. doi: 10.1097/CMR.0000000000000403.

5.

Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections with Obesity.

Garrison CB, Lastwika KJ, Zhang Y, Li CI, Lampe PD.

J Proteome Res. 2017 Jan 6;16(1):274-287. doi: 10.1021/acs.jproteome.6b00611. Epub 2016 Nov 14.

6.

Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

Lastwika KJ, Wilson W 3rd, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, Liu LN, Gills JJ, Dennis PA.

Cancer Res. 2016 Jan 15;76(2):227-38. doi: 10.1158/0008-5472.CAN-14-3362. Epub 2015 Dec 4.

7.

Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss.

Robinson GL, Robinson JP, Lastwika KJ, Holmen SL, Vanbrocklin MW.

Genes Cancer. 2013 Nov;4(11-12):476-85. doi: 10.1177/1947601913513268.

8.

Ink4a/Arf loss promotes tumor recurrence following Ras inhibition.

Vanbrocklin MW, Robinson JP, Lastwika KJ, McKinney AJ, Gach HM, Holmen SL.

Neuro Oncol. 2012 Jan;14(1):34-42. doi: 10.1093/neuonc/nor184. Epub 2011 Oct 20.

9.

Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.

Robinson JP, Vanbrocklin MW, Lastwika KJ, McKinney AJ, Brandner S, Holmen SL.

Oncogene. 2011 Mar 17;30(11):1341-50. doi: 10.1038/onc.2010.513. Epub 2010 Nov 8.

10.

Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice.

VanBrocklin MW, Robinson JP, Lastwika KJ, Khoury JD, Holmen SL.

Pigment Cell Melanoma Res. 2010 Aug;23(4):531-41. doi: 10.1111/j.1755-148X.2010.00717.x. Epub 2010 Apr 23.

Supplemental Content

Loading ...
Support Center